Scientific Papers

Urinary biomarkers for hepatocellular carcinoma: current knowledge for clinicians | Cancer Cell International


  • Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660

    Article 

    Google Scholar
     

  • Llovet JM, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. https://doi.org/10.1038/nrdp.2016.18

    Article 
    PubMed 

    Google Scholar
     

  • Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72:250–61. https://doi.org/10.1016/j.jhep.2019.08.025

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862–73. https://doi.org/10.1016/j.jhep.2017.06.003

    Article 
    PubMed 

    Google Scholar
     

  • Allemani C, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75. https://doi.org/10.1016/s0140-6736(17)33326-3

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Xia YX, et al. [Surgical treatment of primary liver cancer:a report of 10 966 cases]. Zhonghua Wai Ke Za Zhi. 2021;59:6–17. https://doi.org/10.3760/cma.j.cn112139-20201110-00791

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Xie D-Y, Ren Z-G, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surgery and Nutrition 9, 452–463 (2020).

  • Chen T, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics. 2011;10. https://doi.org/10.1074/mcp.M110.004945. M110.004945.

  • Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127:108–12. https://doi.org/10.1053/j.gastro.2004.09.023

    Article 

    Google Scholar
     

  • Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: current best practice and future direction. Gastroenterology. 2019;157:54–64. https://doi.org/10.1053/j.gastro.2019.02.049

    Article 
    PubMed 

    Google Scholar
     

  • Collier J, SHerman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273–8. https://doi.org/10.1002/hep.510270140

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Omata M, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hep Intl. 2017;11:317–70. https://doi.org/10.1007/s12072-017-9799-9

    Article 

    Google Scholar
     

  • Bruix J, SHerman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2. https://doi.org/10.1002/hep.24199

    Article 
    PubMed 

    Google Scholar
     

  • Dinges SS, et al. Cancer metabolomic markers in urine: evidence, techniques and recommendations. Nat Rev Urol. 2019;16:339–62. https://doi.org/10.1038/s41585-019-0185-3

    Article 
    PubMed 

    Google Scholar
     

  • Gao Y. Urine-an untapped goldmine for biomarker discovery? Sci China Life Sci. 2013;56:1145–6. https://doi.org/10.1007/s11427-013-4574-1

    Article 
    PubMed 

    Google Scholar
     

  • Zhou G, et al. Urine mir-93-5p is a promising biomarker for early detection of HBV-related hepatocellular carcinoma. Eur J Surg Oncol. 2022;48:95–102. https://doi.org/10.1016/j.ejso.2021.06.015

    Article 
    PubMed 

    Google Scholar
     

  • Tsai JF, et al. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma. Br J Cancer. 1997;75:1460–6. https://doi.org/10.1038/bjc.1997.250

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Abdelsameea E, et al. Urine Neutrophil Gelatinase-Associated Lipocalin a possible diagnostic marker for Egyptian Hepatocellular Carcinoma Patients. Asian Pac J Cancer Prev. 2020;21:2259–64. https://doi.org/10.31557/apjcp.2020.21.8.2259

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Abdalla MA, Haj-Ahmad Y. Promising urinary protein biomarkers for the early detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J Cancer. 2012;3:390–403. https://doi.org/10.7150/jca.4280

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hann HW, et al. Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma. Hepatoma Res. 2017;3:105–11. https://doi.org/10.20517/2394-5079.2017.15

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ross RK, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet. 1992;339:943–6. https://doi.org/10.1016/0140-6736(92)91528-g

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kim JU, et al. Hepatocellular carcinoma: review of disease and tumor biomarkers. World J Hepatol. 2016;8:471–84. https://doi.org/10.4254/wjh.v8.i10.471

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wang J, et al. Development and evaluation of Novel Statistical Methods in urine biomarker-based Hepatocellular Carcinoma Screening. Sci Rep. 2018;8:3799. https://doi.org/10.1038/s41598-018-21922-9

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Su YH, Lin SY, Song W, Jain S. DNA markers in molecular diagnostics for hepatocellular carcinoma. Expert Rev Mol Diagn. 2014;14:803–17. https://doi.org/10.1586/14737159.2014.946908

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yeh YC, et al. Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res. 1987;47:896–901.

    CAS 
    PubMed 

    Google Scholar
     

  • Bedossa P, Peltier E, Terris B, Franco D, Poynard T. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology. 1995;21:760–6.

    CAS 
    PubMed 

    Google Scholar
     

  • Tsai JF, et al. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. Br J Cancer. 1997;76:244–50. https://doi.org/10.1038/bjc.1997.369

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hirose J, et al. Human neutrophil elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biol Pharm Bull. 1998;21:651–6. https://doi.org/10.1248/bpb.21.651

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Noie T, et al. Kinetics of urinary trypsin inhibitor in patients undergoing partial hepatectomy. Scand J Gastroenterol. 2001;36:410–6. https://doi.org/10.1080/003655201300051270

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Lin SD, et al. Plasma and urine levels of urinary trypsin inhibitor in patients with chronic liver diseases and hepatocellular carcinoma. J Gastroenterol Hepatol. 2004;19:327–32. https://doi.org/10.1111/j.1440-1746.2003.03221.x

    Article 
    PubMed 

    Google Scholar
     

  • Flower DR. The lipocalin protein family: structure and function. Biochem J. 1996;318(Pt 1):1–14. https://doi.org/10.1042/bj3180001

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta. 2012;1826:129–69. https://doi.org/10.1016/j.bbcan.2012.03.008

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhang Y, Fan Y, Mei Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. Cancer Epidemiol. 2012;36:e294–299. https://doi.org/10.1016/j.canep.2012.05.012

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Roli L, Pecoraro V, Trenti T. Can NGAL be employed as prognostic and diagnostic biomarker in human cancers? A systematic review of current evidence. Int J Biol Markers. 2017;32:e53–e61. https://doi.org/10.5301/jbm.5000245

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zheng H, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006;26:3579–83.

    CAS 
    PubMed 

    Google Scholar
     

  • Giannelli G, et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer. 2002;97:425–31. https://doi.org/10.1002/ijc.1635

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tan W, et al. Inhibition of MMP-2 expression enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by suppressing the PI3K/AKT/mTOR pathway. Oncol Res. 2017;25:1543–53. https://doi.org/10.3727/096504017×14886444100783

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Suh YG, Lee EJ, Cha H, Yang SH, Seong J. Prognostic values of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma after radiotherapy. Dig Dis. 2014;32:725–32. https://doi.org/10.1159/000368010

    Article 
    PubMed 

    Google Scholar
     

  • Olszowy P, Buszewski B. Urine sample preparation for proteomic analysis. J Sep Sci. 2014;37:2920–8. https://doi.org/10.1002/jssc.201400331

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Theodorescu D, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006;7:230–40. https://doi.org/10.1016/s1470-2045(06)70584-8

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Metzger J, et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut. 2013;62:122–30. https://doi.org/10.1136/gutjnl-2012-302047

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zhang C, et al. Urine proteome profiling predicts Lung Cancer from Control cases and other tumors. EBioMedicine. 2018;30:120–8. https://doi.org/10.1016/j.ebiom.2018.03.009

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Huang CH, et al. Onco-proteogenomics identifies urinary S100A9 and GRN as potential combinatorial biomarkers for early diagnosis of hepatocellular carcinoma. BBA Clin. 2015;3:205–13. https://doi.org/10.1016/j.bbacli.2015.02.004

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhao Y, et al. Identification of noninvasive diagnostic biomarkers for hepatocellular carcinoma by urinary proteomics. J Proteom. 2020;225:103780. https://doi.org/10.1016/j.jprot.2020.103780

    Article 
    CAS 

    Google Scholar
     

  • Zhan Z, et al. Urine alpha-fetoprotein and orosomucoid 1 as biomarkers of hepatitis B virus-associated hepatocellular carcinoma. Am J Physiology-Gastrointestinal Liver Physiol. 2020;318:G305–12. https://doi.org/10.1152/ajpgi.00267.2019

    Article 
    CAS 

    Google Scholar
     

  • Bannaga A, et al. Pathophysiological implications of urinary peptides in Hepatocellular Carcinoma. Cancers (Basel). 2021;13. https://doi.org/10.3390/cancers13153786

  • ZimMermann U, et al. Chromosomal aberrations in hepatocellular carcinomas: relationship with pathological features. Hepatology. 1997;26:1492–8. https://doi.org/10.1053/jhep.1997.v26.pm0009397989

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wu R, et al. S100A9 promotes the proliferation and invasion of HepG2 hepatocellular carcinoma cells via the activation of the MAPK signaling pathway. Int J Oncol. 2013;42:1001–10. https://doi.org/10.3892/ijo.2013.1796

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ho JC, et al. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology. 2008;47:1524–32. https://doi.org/10.1002/hep.22191

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Belczacka I, et al. Proteomics biomarkers for solid tumors: current status and future prospects. Mass Spectrom Rev. 2019;38:49–78. https://doi.org/10.1002/mas.21572

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML. The role of circulating free DNA and MicroRNA in non-invasive diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma. Int J Mol Sci. 2018;19. https://doi.org/10.3390/ijms19041007

  • Su YH, et al. Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn. 2004;6:101–7. https://doi.org/10.1016/s1525-1578(10)60497-7

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lin SY, et al. A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine. J Mol Diagn. 2011;13:474–84. https://doi.org/10.1016/j.jmoldx.2011.05.005

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kim AK, et al. Urine DNA biomarkers for hepatocellular carcinoma screening. Br J Cancer. 2022;126:1432–8. https://doi.org/10.1038/s41416-022-01706-9

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhang A, Lee T-J, Jain S, Su Y-H. in IEEE International Conference on Bioinformatics and Biomedicine (BIBM) – Human Genomics 2820–2825 (2018).

  • Jain S, et al. Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis. Hepatol Res. 2015;45:1110–23. https://doi.org/10.1111/hepr.12449

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zhao Y, Song Y, Yao L, Song G, Teng C. Circulating microRNAs: promising biomarkers involved in several cancers and other Diseases. DNA Cell Biol. 2017;36:77–94. https://doi.org/10.1089/dna.2016.3426

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ziogas IA, Sioutas G, Mylonas KS, Tsoulfas G. Role of MicroRNA in the diagnosis and management of Hepatocellular Carcinoma. Microrna. 2020;9:25–40. https://doi.org/10.2174/2211536608666190619155406

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Mitchell PS, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8. https://doi.org/10.1073/pnas.0804549105

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Abdalla MA, Haj-Ahmad Y. Promising candidate urinary MicroRNA biomarkers for the early detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J Cancer. 2012;3:19–31. https://doi.org/10.7150/jca.3.19

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Świtlik WZ, et al. Forms of diagnostic material as sources of miRNA biomarkers in hepatocellular carcinoma: a preliminary study. Biomark Med. 2019;13:523–34. https://doi.org/10.2217/bmm-2018-0485

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tamori A, et al. Relationship of ornithine decarboxylase activity and histological findings in human hepatocellular carcinoma. Hepatology. 1994;20:1179–86.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kubota S, et al. Urinary polyamines as a tumor marker. Cancer Detect Prev. 1985;8:189–92.

    CAS 
    PubMed 

    Google Scholar
     

  • Antoniello S, Auletta M, Magri P, Pardo F. Urinary excretion of free and acetylated polyamines in hepatocellular carcinoma. Int J Biol Markers. 1998;13:92–7.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Enjoji M, et al. Clinical significance of urinary N1,N12-diacetylspermine levels in patients with hepatocellular carcinoma. Int J Biol Markers. 2004;19:322–7. https://doi.org/10.5301/jbm.2008.4964

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Yu C, et al. Quantification of free polyamines and their metabolites in biofluids and liver tissue by UHPLC-MS/MS: application to identify the potential biomarkers of hepatocellular carcinoma. Anal Bioanal Chem. 2015;407:6891–7. https://doi.org/10.1007/s00216-015-8860-6

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Liu R, et al. Determination of polyamine metabolome in plasma and urine by ultrahigh performance liquid chromatography-tandem mass spectrometry method: application to identify potential markers for human hepatic cancer. Anal Chim Acta. 2013;791:36–45. https://doi.org/10.1016/j.aca.2013.06.044

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • DeRubertis FR, Chayoth R, Field JB. The content and metabolism of cyclic adenosine 3’, 5’-monophosphate and cyclic guanosine 3’, 5’-monophosphate in adenocarcinoma of the human colon. J Clin Invest. 1976;57:641–9. https://doi.org/10.1172/jci108320

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hickie RA, Walker CM, Croll GA. Decreased basal cyclic adenosine 3’,5’-monophosphate levels in Morris hepatoma 5123 t.c. (h). Biochem Biophys Res Commun. 1974;59:167–73. https://doi.org/10.1016/s0006-291x(74)80189-0

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Dusheiko GM, Levin J, Kew MC. Cyclic nucleotides in biological fluids in hepatocellular carcinoma. Cancer. 1981;47:113–8. https://doi.org/10.1002/1097-0142(19810101)47:1%3C113::aid-cncr2820470119%3E3.0.co;2-7

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Turner GA, et al. Urine cyclic nucleotide concentrations in cancer and other conditions; cyclic GMP: a potential marker for cancer treatment. J Clin Pathol. 1982;35:800–6. https://doi.org/10.1136/jcp.35.8.800

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Deugnier Y, et al. Serum α-L-Fucosidase: a new marker for the diagnosis of primary hepatic carcinoma? Hepatology. 1984;4:889–92. https://doi.org/10.1002/hep.1840040516

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sakai T, et al. Rapid, simple enzymatic assay of free L-fucose in serum and urine, and its use as a marker for cancer, cirrhosis, and gastric ulcers. Clin Chem. 1990;36:474–6.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Liu ZZ, et al. Cytochrome P450 family members are associated with fast-growing hepatocellular carcinoma and patient survival: an integrated analysis of gene expression profiles. Saudi J Gastroenterol. 2019;25:167–75. https://doi.org/10.4103/sjg.SJG_290_18

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bannaga AS, Tyagi H, Daulton E, Covington JA, Arasaradnam RP. Exploratory study using urinary volatile Organic Compounds for the detection of Hepatocellular Carcinoma. Molecules. 2021;26. https://doi.org/10.3390/molecules26092447

  • Bannaga AS, Kvasnik F, Persaud KC, Arasaradnam R. Differentiating cancer types using a urine test for volatile organic compounds. J Breath Res. 2021;15. https://doi.org/10.1088/1752-7163/abc36b

  • Nicholson JK, Lindon JC, Holmes E. Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181–9. https://doi.org/10.1080/004982599238047

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Everett JR. A new paradigm for known metabolite identification in metabonomics/metabolomics: metabolite identification efficiency. Comput Struct Biotechnol J. 2015;13:131–44. https://doi.org/10.1016/j.csbj.2015.01.002

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wu H, et al. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta. 2009;648:98–104. https://doi.org/10.1016/j.aca.2009.06.033

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wang KX, Du GH, Qin XM, Gao L. 1H-NMR-based metabolomics reveals the biomarker panel and molecular mechanism of hepatocellular carcinoma progression. Anal Bioanal Chem. 2022;414:1525–37. https://doi.org/10.1007/s00216-021-03768-9

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Emwas AH. The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research. Methods Mol Biol. 2015;1277:161–93. https://doi.org/10.1007/978-1-4939-2377-9_13

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Cox IJ, et al. Urinary nuclear magnetic resonance spectroscopy of a bangladeshi cohort with hepatitis-B hepatocellular carcinoma: a biomarker corroboration study. World J Gastroenterol. 2016;22:4191–200. https://doi.org/10.3748/wjg.v22.i16.4191

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Shariff MI, et al. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a nigerian population. J Proteome Res. 2010;9:1096–103. https://doi.org/10.1021/pr901058t

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Shariff MIF, et al. Urinary metabolic biomarkers of Hepatocellular Carcinoma in an Egyptian Population: a validation study. J Proteome Res. 2011;10:1828–36. https://doi.org/10.1021/pr101096f

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Shariff MI, et al. Urinary metabotyping of Hepatocellular Carcinoma in a UK Cohort using Proton Nuclear magnetic resonance spectroscopy. J Clin Exp Hepatol. 2016;6:186–94. https://doi.org/10.1016/j.jceh.2016.03.003

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ladep NG, et al. Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans. Hepatology. 2014;60:1291–301. https://doi.org/10.1002/hep.27264

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Li ZF, et al. Gas chromatography/time-of-flight mass spectrometry-based metabonomics of hepatocarcinoma in rats with lung metastasis: elucidation of the metabolic characteristics of hepatocarcinoma at formation and metastasis. Rapid Commun Mass Spectrom. 2010;24:2765–75. https://doi.org/10.1002/rcm.4703

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Osman D, Ali O, Obada M, El-Mezayen H, El-Said H. Chromatographic determination of some biomarkers of liver cirrhosis and hepatocellular carcinoma in Egyptian patients. Biomed Chromatogr. 2017;31. https://doi.org/10.1002/bmc.3893

  • Ye G, et al. Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. J Proteome Res. 2012;11:4361–72. https://doi.org/10.1021/pr300502v

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Liang Q, Liu H, Wang C, Li B. Phenotypic characterization analysis of human hepatocarcinoma by urine Metabolomics Approach. Sci Rep. 2016;6:19763. https://doi.org/10.1038/srep19763

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li Y, et al. A novel approach to transforming a non-targeted metabolic profiling method to a pseudo-targeted method using the retention time locking gas chromatography/mass spectrometry-selected ions monitoring. J Chromatogr A. 2012;1255:228–36. https://doi.org/10.1016/j.chroma.2012.01.076

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Shao Y, et al. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery. J Proteome Res. 2015;14:906–16. https://doi.org/10.1021/pr500973d

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bruzas I, Lum W, Gorunmez Z, Sagle L. Advances in surface-enhanced Raman spectroscopy (SERS) substrates for lipid and protein characterization: sensing and beyond. Analyst. 2018;143:3990–4008. https://doi.org/10.1039/c8an00606g

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Dawuti W, et al. Urine surface-enhanced Raman spectroscopy combined with SVM algorithm for rapid diagnosis of liver cirrhosis and hepatocellular carcinoma. Photodiagnosis Photodyn Ther. 2022;38:102811. https://doi.org/10.1016/j.pdpdt.2022.102811

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Groopman JD, DeMatos P, Egner PA, Love-Hunt A, Kensler TW. Molecular dosimetry of urinary aflatoxin-N7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1,2-dithiole-3-thione in rats. Carcinogenesis. 1992;13:101–6. https://doi.org/10.1093/carcin/13.1.101

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wang LY et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 67, 620–625, https://doi.org/10.1002/(sici)1097-0215(19960904)67:5<620::Aid-ijc5>3.0.Co;2-w (1996).

  • Hatch MC, et al. Urinary aflatoxin levels, hepatitis-B virus infection and hepatocellular carcinoma in Taiwan. Int J Cancer. 1993;54:931–4. https://doi.org/10.1002/ijc.2910540611

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol. 2012;56:704–13. https://doi.org/10.1016/j.jhep.2011.09.020

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol. 2010;38:96–109. https://doi.org/10.1177/0192623309356453

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bartsch H, Nair J. Oxidative stress and lipid peroxidation-derived DNA-lesions in inflammation driven carcinogenesis. Cancer Detect Prev. 2004;28:385–91. https://doi.org/10.1016/j.cdp.2004.07.004

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Yuan J-M, et al. Prediagnostic levels of urinary 8-epi-prostaglandin F-2 alpha and prostaglandin E-2 metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma. Carcinogenesis. 2019;40:989–97. https://doi.org/10.1093/carcin/bgy180

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ma X, et al. Pre-diagnostic urinary 15-F(2t) -isoprostane level and liver cancer risk: results from the Shanghai Women’s and men’s Health Studies. Int J Cancer. 2018;143:1896–903. https://doi.org/10.1002/ijc.31591

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wu HC, et al. Urinary 15-F2t-isoprostane, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Carcinogenesis. 2008;29:971–6. https://doi.org/10.1093/carcin/bgn057

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     



  • Source link